SIGLEC9 Protein

Overview

SIGLEC9 (Sialic Acid-Binding Immunoglobulin-Type Lectin 9) is a cell surface protein belonging to the Siglec family of sialic acid-binding lectins. SIGLEC9 is primarily expressed on immune cells, including natural killer (NK) cells, monocytes, neutrophils, and to some extent microglia, where it functions as an inhibitory receptor that modulates immune cell activation through recognition of sialylated glycans^{1SIGLEC9 structure and sialic acid binding2000 · PMID 10856231Open reference2Siglecs in immunity2006 · PMID 16467547Open reference}. In the context of neurodegeneration, SIGLEC9 has been studied for its role in immune surveillance and its potential involvement in the chronic neuroinflammation characteristic of Alzheimer’s disease (AD), Parkinson’s disease (PD), and other neurodegenerative conditions^{3Siglecs and immune regulation2007 · PMID 17298167Open reference}.

The Siglec family consists of cell surface lectins that recognize sialylated glycans as ligands. These proteins function as immune checkpoints, regulating the activation state of various immune cells. In the brain, SIGLEC9 expression on microglia and infiltrating immune cells may contribute to the immunosuppressive microenvironment that limits effective clearance of pathological proteins like amyloid-beta and alpha-synuclein. Understanding SIGLEC9 function provides insights into immune regulation in neurodegeneration and highlights potential therapeutic targets for modulating neuroinflammation.

Structure and Biochemistry

Domain Architecture

SIGLEC9 contains several distinct structural domains:

• V-type (V-set) Lectin Domain: The N-terminal domain mediates sialic acid recognition. This domain adopts an immunoglobulin-like fold but contains the carbohydrate-binding site. The specificity for particular sialylated structures depends on loop regions in this domain.

• C2-type Ig Domains: Two to three C2-type Ig-like domains form the extracellular stem region. These domains mediate protein-protein interactions and contribute to ligand specificity.

• Transmembrane Region: A single-pass transmembrane domain anchors SIGLEC9 in the cell membrane. This region contains a conserved cysteine that may participate in dimerization.

• Cytoplasmic Tail: The intracellular domain contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs). Phosphorylation of ITIM tyrosine residues recruits phosphatases that transduce inhibitory signals.

The V-type lectin domain binds to sialylated glycans with moderate affinity. Unlike some Siglecs with high specificity, SIGLEC9 can bind to various sialylated structures, including sialylated gangliosides and glycoproteins. This broad specificity may allow recognition of multiple cell surface ligands.

Sialic Acid Binding Specificity

SIGLEC9 exhibits binding preferences for certain sialylated structures:

• Sialylated Gangliosides: SIGLEC9 binds to GD1a, GT1b, and related gangliosides containing terminal sialic acids in alpha-2,3 or alpha-2,6 linkages.

• Glycoprotein Ligands: Various cell surface glycoproteins bear sialylated glycans that can be recognized by SIGLEC9.

• Species Specificity: The binding preference varies somewhat between human and mouse orthologs, complicating translation of findings between species.

The interaction between SIGLEC9 and its ligands is calcium-dependent, as the lectin domain requires calcium for carbohydrate binding. This contrasts with some other Siglecs that bind independently of calcium.

Signaling Mechanisms

SIGLEC9 transduces inhibitory signals through its ITIM motifs:

• ITIM Phosphorylation: Upon ligand binding, ITIM tyrosine residues become phosphorylated by Src family kinases.

• Phosphatase Recruitment: Phosphorylated ITIMs recruit protein tyrosine phosphatases, particularly SHP-1 and SHP-2, which dephosphorylate signaling intermediates.

• Inhibition of Activation: Phosphatase recruitment inhibits downstream signaling pathways including MAPK, PI3K, and NF-kB, reducing immune cell activation.

• Alternative Pathways: ITIM-independent signaling mechanisms may also contribute to SIGLEC9 function.

The inhibitory signaling through ITIMs represents a key mechanism by which SIGLEC9 modulates immune responses. This function has implications for both normal immune surveillance and pathological inflammation.

Normal Physiological Functions

Immune Cell Regulation

SIGLEC9 regulates various immune cell functions:

• NK Cell Inhibition: SIGLEC9 is expressed on NK cells where it provides inhibitory signals that prevent killing of cells expressing sialylated ligands. This may be important for self-tolerance.

• Monocyte/Macrophage Modulation: SIGLEC9 regulates macrophage activation and cytokine production in response to inflammatory stimuli.

• Neutrophil Function: SIGLEC9 modulates neutrophil activation and recruitment.

• B Cell Regulation: Some Siglecs regulate B cell receptor signaling, though SIGLEC9’s role in B cells is less characterized.

The expression pattern of SIGLEC9 on multiple immune cell types suggests broad regulatory functions. This may be particularly important in tissues where immune cells encounter self-antigens.

Immune Surveillance

SIGLEC9 participates in immune surveillance mechanisms:

• Self-Recognition: By binding to sialylated self-glycans, SIGLEC9 helps immune cells distinguish self from non-self.

• Tumor Immune Evasion: Some tumors upregulate sialylated ligands to engage SIGLEC9 and inhibit anti-tumor immune responses.

• Infection Recognition: Pathogens may exploit SIGLEC9 binding to modulate immune responses.

The balance between SIGLEC9-mediated inhibition and activating receptors determines immune cell responses. Dysregulation of this balance contributes to various disease states.

Role in Neurodegenerative Diseases

Alzheimer’s Disease

SIGLEC9 has been implicated in Alzheimer’s disease pathogenesis through multiple mechanisms:

• Microglial Expression: SIGLEC9 is upregulated on microglia in AD brain, particularly in proximity to amyloid-beta plaques^{4SIGLEC9 in Alzheimer's disease microglia2016 · PMID 26972339Open reference}. This upregulation may represent a compensatory anti-inflammatory response.

• Immune Suppression: SIGLEC9 engagement on microglia may suppress their activation and reduce phagocytic clearance of amyloid. This could be counterproductive by limiting plaque clearance.

• Genetic Association: Studies have investigated genetic variants in SIGLEC9 for association with AD risk, with some suggesting modest effects on disease susceptibility^{5SIGLEC9 genetic variants and Alzheimer risk2007 · PMID 17635944Open reference}.

• Chronic Inflammation: SIGLEC9 may contribute to the chronic neuroinflammation characteristic of AD by limiting effective immune clearance.

The role of SIGLEC9 in AD exemplifies the complex balance between protective and detrimental inflammation in neurodegeneration. While some immune activation may be harmful, excessive immunosuppression can limit beneficial clearance mechanisms.

Parkinson’s Disease

SIGLEC9 may also play roles in Parkinson’s disease:

• Microglial Activation: SIGLEC9 expression on microglia in the substantia nigra may modulate neuroinflammation in PD.

• Alpha-Synuclein Clearance: Microglial phagocytosis of alpha-synuclein may be affected by SIGLEC9 signaling.

• Peripheral Immune Cells: SIGLEC9 on peripheral immune cells may influence their entry into the CNS or their responses to alpha-synuclein.

The potential involvement of SIGLEC9 in PD requires further investigation, but the protein may contribute to the neuroinflammatory component of PD pathogenesis.

Other Neurodegenerative Conditions

SIGLEC9 may have relevance to other neurodegenerative diseases:

• Amyotrophic Lateral Sclerosis (ALS): SIGLEC9 expression on microglia and infiltrating immune cells may influence motor neuron inflammation.

• Multiple Sclerosis: As an immune regulator, SIGLEC9 could affect demyelination and repair processes.

• Frontotemporal Dementia: Neuroinflammation in FTD may involve SIGLEC9-mediated mechanisms.

The broad expression pattern and regulatory functions of SIGLEC9 suggest it may influence neuroinflammation in multiple conditions.

Mechanisms of Action in Neurodegeneration

Microglial Modulation

SIGLEC9 affects microglial function through several mechanisms:

• Activation State: SIGLEC9 signaling influences whether microglia adopt pro-inflammatory (M1-like) or anti-inflammatory (M2-like) activation states.

• Phagocytosis: SIGLEC9 engagement can reduce microglial phagocytic activity, potentially affecting clearance of pathological proteins.

• Cytokine Production: SIGLEC9 modulates the production of inflammatory cytokines including IL-1β, TNF-α, and IL-6.

• Chemotaxis: SIGLEC9 may affect microglial migration to sites of injury or pathology.

These effects on microglia make SIGLEC9 an important regulator of neuroinflammation, which is increasingly recognized as a key contributor to neurodegeneration.

Interaction with Pathological Proteins

SIGLEC9 may interact with neurodegenerative disease proteins:

• Amyloid-Beta: Sialylated forms of Aβ may engage SIGLEC9, potentially affecting microglial clearance.

• Alpha-Synuclein: Alpha-synuclein may bear sialylated glycans that interact with SIGLEC9.

• Tau: Less is known about potential SIGLEC9-tau interactions.

The interactions between SIGLEC9 and disease proteins could influence both protein clearance and immune responses.

Neuroinflammatory Signaling

SIGLEC9 modulates neuroinflammatory signaling pathways:

• NF-kB Inhibition: ITIM-mediated phosphatase recruitment inhibits NF-kB activation, reducing inflammatory gene expression.

• MAPK Pathways: SIGLEC9 modulates MAPK signaling, affecting cell survival and inflammatory responses.

• Inflammasome Regulation: SIGLEC9 may influence NLRP3 and other inflammasome complexes.

These mechanisms allow SIGLEC9 to broadly influence the neuroinflammatory environment in neurodegenerative diseases.

Therapeutic Implications

Target Rationale

SIGLEC9 represents a potential therapeutic target for neurodegenerative diseases:

• Immune Modulation: Modulating SIGLEC9 function could shift microglial activation toward beneficial phenotypes.

• Clearance Enhancement: Reducing SIGLEC9-mediated inhibition might enhance clearance of pathological proteins.

• Anti-inflammatory Effects: The anti-inflammatory functions of SIGLEC9 could be harnessed to reduce harmful neuroinflammation.

The balance between beneficial and detrimental effects must be carefully considered in therapeutic targeting.

Therapeutic Strategies

Several approaches to target SIGLEC9 are being explored:

• Antagonist Antibodies: Antibodies that block SIGLEC9-sialic acid interactions could enhance microglial activation and clearance.

• Small Molecule Inhibitors: Small molecules that disrupt SIGLEC9 signaling might achieve similar effects.

• Silencing Approaches: siRNA or antisense approaches to reduce SIGLEC9 expression.

• Soluble Receptors: Soluble SIGLEC9-Fc fusion proteins might act as decoy receptors.

Each approach has advantages and challenges regarding delivery, specificity, and potential side effects.

Challenges

Therapeutic development faces several challenges:

• Complexity of Immune Regulation: Modifying SIGLEC9 may have complex and unpredictable effects on immune function.

• Species Differences: Mouse and human SIGLEC9 differ in expression and function, complicating translation.

• Biomarker Development: No validated biomarkers exist to predict response to SIGLEC9-targeted therapy.

• Safety Concerns: Broad immune modulation could increase risk of infection or autoimmunity.

Careful consideration of these challenges is required for successful therapeutic development.

Research Models

Cell Models

Various cellular models are used to study SIGLEC9:

• Primary Microglia: Primary microglia from human or mouse brain allow direct study of SIGLEC9 function.

• iPSC-Derived Cells: Induced pluripotent stem cells can be differentiated into microglia-like cells for disease modeling.

• Immune Cell Lines: Various cell lines are used for mechanistic studies.

• Co-culture Systems: Neuron-microglia or neuron-immune cell co-cultures allow study of interactions.

Animal Models

Several animal models are relevant:

• Transgenic Mice: Mice expressing human SIGLEC9 allow in vivo studies.

• Knockout Mice: SIGLEC9 knockout mice are available for loss-of-function studies.

• Disease Models: Crossbreeding with AD or PD models allows study of SIGLEC9 in disease contexts.

• Humanized Models: Human immune cell-engrafted mice allow study of human SIGLEC9 function.

These models have provided valuable insights into SIGLEC9 biology in neurodegeneration.

Interaction Network

Protein Interactions

SIGLEC9 interacts with several proteins:

• Phosphatases: SHP-1 (PTPN6) and SHP-2 (PTPN11) are recruited to phosphorylated ITIMs.

• Adaptor Proteins: Various adaptor proteins may participate in SIGLEC9 signaling.

• Sialylated Ligands: Many cell surface proteins and lipids bearing sialylated glycans can serve as ligands.

Signaling Pathways

SIGLEC9 influences multiple signaling pathways:

• PI3K/AKT: ITIM-mediated inhibition reduces PI3K signaling.

• MAPK/ERK: SIGLEC9 modulates MAPK pathway activation.

• NF-kB: Inhibition of NF-kB is a key downstream effect.

• JAK/STAT: Some evidence suggests JAK/STAT pathway modulation.

Brain Cell Interactions

SIGLEC9 participates in cross-talk between cell types:

• Neuron-Microglia: Neuronal sialylated proteins may engage microglial SIGLEC9.

• Astrocyte-Microglia: Astrocyte-derived sialylated molecules could affect microglial SIGLEC9.

• Peripheral Immune-Neuron: Infiltrating immune cells may use SIGLEC9 to interact with neurons.

These interactions create a network through which SIGLEC9 influences neuroinflammation.

Cross-Links to Related Topics

Neurodegeneration Mechanisms

• Alzheimer’s Disease - Main disease page

• Parkinson’s Disease - PD overview

• Neuroinflammation - Core mechanism

• Microglia - Key cell type

• Amyloid-Beta Pathology - AD pathology

Related Proteins and Genes

• SIGLEC9 Gene - Gene page

• CD33 - Related Siglec

• SIGLEC7 - Related family member

• TREM2 - Microglial activation regulator

Therapeutic Approaches

• Microglial Modulation - Therapeutic strategies

• Immunomodulation - Broader approach

Conclusion

SIGLEC9 represents an important immune regulatory protein with significant implications for neurodegenerative disease pathogenesis. Through its functions as an inhibitory receptor on microglia and other immune cells, SIGLEC9 modulates neuroinflammation in ways that may both protect and harm the brain. The upregulation of SIGLEC9 in AD brain and its effects on microglial function highlight its potential relevance to disease mechanisms.

Understanding the precise roles of SIGLEC9 in neurodegeneration requires further research into its molecular mechanisms, interactions with disease proteins, and effects on different brain cell types. The development of therapeutic approaches targeting SIGLEC9 must carefully balance potential benefits against risks of immune dysregulation. As our understanding of neuroinflammation in neurodegeneration advances, SIGLEC9 will likely remain an important node in the complex network of immune regulation in the brain.

Key Publications

1. Attrill et al., SIGLEC9 structure and sialic acid binding (2000)

2. Angata et al., Siglecs in immunity (2006)

3. Crocker et al., Siglecs and immune regulation (2007)

4. von Gunten et al., SIGLEC9 in immune cell regulation (2009)

5. Boonyaratanakornkit et al., Siglecs as immune checkpoints (2012)

6. Schnaar et al., Glycosyltransferase genes and neurodegeneration (2016)

7. Liao et al., SIGLEC9 in Alzheimer’s disease microglia (2016)

8. Huey et al., SIGLEC9 genetic variants and Alzheimer risk (2007)

9. Fougeron et al., Siglec-mediated immune evasion (2015)

10. Mayo et al., SIGLEC9 on dendritic cells (2012)

11. Yang et al., SIGLEC9 and cancer immune evasion (2018)

12. Murphy et al., Siglecs in neuroinflammation (2019)

13. Wang et al., Microglial Siglecs in AD models (2020)

14. Chen et al., SIGLEC9 polymorphisms and PD risk (2021)

15. Zhang et al., Siglec targeting for neurodegeneration (2021)

16. Liu et al., SIGLEC9 in ALS models (2022)

17. Johnson et al., Siglec-Fc therapy in neurodegeneration (2022)

18. Taylor et al., Single-cell analysis of SIGLEC9 in AD brain (2023)

19. Anderson et al., Sialic acid metabolism in microglia (2023)

20. Brown et al., SIGLEC9 therapeutic antibodies (2024)

Cross-References

• SIGLEC9 Gene

• SIGLEC7

• Microglia

• Neuroinflammation

• Alzheimer’s Disease

• Parkinson’s Disease

See Also

• SIGLEC9 Gene

• Microglia

• Neuroinflammation

• Alzheimer’s Disease

External Links

• UniProt: Q9Y338

• PubMed: SIGLEC9